NO20012636L - Kontrollert frigivelsesformulering som omfatter GNRH-II - Google Patents

Kontrollert frigivelsesformulering som omfatter GNRH-II

Info

Publication number
NO20012636L
NO20012636L NO20012636A NO20012636A NO20012636L NO 20012636 L NO20012636 L NO 20012636L NO 20012636 A NO20012636 A NO 20012636A NO 20012636 A NO20012636 A NO 20012636A NO 20012636 L NO20012636 L NO 20012636L
Authority
NO
Norway
Prior art keywords
gnrh
controlled release
release formulation
formulation
controlled
Prior art date
Application number
NO20012636A
Other languages
English (en)
Norwegian (no)
Other versions
NO20012636D0 (no
Inventor
Steve Qi
Karen Akinsanya
Amanda Hayward
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of NO20012636D0 publication Critical patent/NO20012636D0/no
Publication of NO20012636L publication Critical patent/NO20012636L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/23Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
NO20012636A 1998-12-03 2001-05-29 Kontrollert frigivelsesformulering som omfatter GNRH-II NO20012636L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9826662A GB2344287A (en) 1998-12-03 1998-12-03 Controlled release pharmaceutical formulation
PCT/GB1999/004045 WO2000032218A1 (en) 1998-12-03 1999-12-02 Controlled release formulation comprising gnrh-ii

Publications (2)

Publication Number Publication Date
NO20012636D0 NO20012636D0 (no) 2001-05-29
NO20012636L true NO20012636L (no) 2001-07-12

Family

ID=10843631

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012636A NO20012636L (no) 1998-12-03 2001-05-29 Kontrollert frigivelsesformulering som omfatter GNRH-II

Country Status (22)

Country Link
EP (1) EP1140133A1 (xx)
JP (1) JP2002531411A (xx)
KR (1) KR20010089538A (xx)
CN (1) CN1332635A (xx)
AU (1) AU770676B2 (xx)
BR (1) BR9915943A (xx)
CA (1) CA2353798A1 (xx)
CZ (1) CZ20011893A3 (xx)
EE (1) EE200100293A (xx)
GB (1) GB2344287A (xx)
HR (1) HRP20010421A2 (xx)
HU (1) HUP0104943A3 (xx)
IL (1) IL143496A0 (xx)
MX (1) MXPA01005543A (xx)
NO (1) NO20012636L (xx)
NZ (1) NZ511984A (xx)
PL (1) PL348575A1 (xx)
RU (1) RU2233170C2 (xx)
SK (1) SK7552001A3 (xx)
TR (1) TR200102273T2 (xx)
WO (1) WO2000032218A1 (xx)
ZA (1) ZA200104530B (xx)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909814B1 (en) 2005-07-26 2015-06-24 Georg-August-Universität Göttingen Stiftung öffentlichen Rechts (ohne Bereich Humanmedizin) Peptides for induction and enhancement of apoptosis in tumor cells
GB0616111D0 (en) 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
WO2010111617A2 (en) 2009-03-27 2010-09-30 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
WO2011032099A1 (en) 2009-09-11 2011-03-17 The Board Of Trustees Of The University Of Illinois Methods of treating diastolic dysfunction and related conditions
WO2011056572A1 (en) 2009-10-27 2011-05-12 The Board Of Trustees Of The University Of Illinois Methods of diagnosing diastolic dysfunction
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
MX2012008603A (es) 2010-01-27 2013-01-25 Univ Indiana Res & Tech Corp Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
DK2547359T3 (en) 2010-03-15 2016-06-06 The Board Of Trustees Of The Univ Of Illionis Inhibitors of beta integrin G-protein alpha subunit-BINDING INTERACTIONS
EP2582719B1 (en) 2010-06-16 2016-08-10 Indiana University Research and Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
US20120004182A1 (en) 2010-07-02 2012-01-05 Carsten Gruendker Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells
WO2012087943A2 (en) 2010-12-20 2012-06-28 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
PE20140186A1 (es) 2010-12-22 2014-02-13 Univ Indiana Res & Tech Corp Analogos de glucagon que presentan actividad de receptor de gip
GEP20176629B (en) 2011-06-22 2017-02-27 Indiana Unversity Research And Tech Corporation Glucagon/glp-1 receptor co-agonists
US9415123B2 (en) 2011-10-10 2016-08-16 The Regents Of The University Of Michigan Polymeric nanoparticles for ultrasound imaging and therapy
KR20140097151A (ko) 2011-11-17 2014-08-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루코코르티코이드 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
BR112014015156A2 (pt) 2011-12-20 2020-10-27 Indiana University Research And Technology Corporation análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira
MX2014015205A (es) 2012-06-14 2015-08-14 Ambrx Inc Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear.
CA2877127A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Analogs of glucagon exhibiting gip receptor activity
JP6311708B2 (ja) 2012-06-21 2018-04-18 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation Gip受容体活性を示すグルカゴンアナローグ
CN108383902A (zh) 2012-09-26 2018-08-10 印第安纳大学研究及科技有限公司 胰岛素类似物二聚体
KR20150131213A (ko) 2013-03-14 2015-11-24 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 인슐린-인크레틴 접합체들
WO2015120187A1 (en) 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
JP7264592B2 (ja) 2015-01-26 2023-04-25 ザ ユニバーシティー オブ シカゴ IL13Rα2結合剤及び癌治療におけるその使用
US20180170992A1 (en) 2015-01-26 2018-06-21 The University Of Chicago CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
CN104789524A (zh) * 2015-04-30 2015-07-22 四川大学 骨质疏松大鼠原代成骨细胞分离培养方法及应用
US20180201937A1 (en) 2015-08-04 2018-07-19 The University Of Chicago Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
KR20190117541A (ko) * 2017-01-20 2019-10-16 이뮨 시스템 레귤레이션 홀딩 에이비 신규 화합물 (이뮤노렐린)
MX2020000190A (es) 2017-06-30 2020-07-22 Amgen Inc Métodos para tratar la insuficiencia cardíaca con activadores de sarcómero cardíaco.
CR20200099A (es) 2017-08-03 2020-07-24 Amgen Inc Muteínas de interleucina 21 y métodos de tratamiento
SG11202001499WA (en) 2017-09-08 2020-03-30 Amgen Inc Inhibitors of kras g12c and methods of using the same
EP3826667B1 (en) 2017-09-18 2024-04-17 The Regents of the University of California Claudin6 antibodies and methods of treating cancer
UY38049A (es) 2018-01-12 2019-07-31 Amgen Inc Anti-pd-1 anticuerpos y métodos de tratamiento
WO2020055913A1 (en) 2018-09-10 2020-03-19 Cardax, Inc. Methods of reducing- c-reactive protein and/or treating cardiovascular disease
WO2020191342A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
CN114206934A (zh) 2019-03-20 2022-03-18 加利福尼亚大学董事会 密封蛋白-6双特异性抗体
CN112955181A (zh) * 2019-03-26 2021-06-11 新型医药公司 一种长效脂肪酸缀合的GnRH衍生物及含其的药物组合物
CA3136496A1 (en) 2019-04-09 2020-10-15 The Board Of Trustees Of The University Of Illinois Drug adsorbed highly porous activated carbon for enhanced drug delivery
US20230190725A1 (en) 2019-04-29 2023-06-22 The Board Of Trustees Of The University Of Illinois Mek inhibitors for corneal scarring and neovascularization
CA3132656A1 (en) 2019-04-30 2020-11-05 Instituto De Medicina Molecular Joao Lobo Antunes Rank pathway inhibitors in combination with cdk inhibitors
AU2020303986A1 (en) 2019-06-24 2021-12-09 Amgen Inc. Inhibition of SIRP-gamma for cancer treatment
EP4021454A1 (en) 2019-08-30 2022-07-06 Research Institute at Nationwide Children's Hospital Copper-atsm for treating neurodegenerative disorders associated with mitochondrial dysfunction
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Tigit及cd112r阻斷
JP2024504696A (ja) 2021-01-20 2024-02-01 バイオアントレ エルエルシー Ctla4結合性タンパク質およびがんを処置する方法
WO2023137161A1 (en) 2022-01-14 2023-07-20 Amgen Inc. Triple blockade of tigit, cd112r, and pd-l1
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
DE3414595A1 (de) * 1984-04-18 1985-10-31 Hoechst Ag, 6230 Frankfurt Verwendung von gonadoliberin und gonadoliberinagonisten zur behandlung klimakterischer beschwerden
US4540513A (en) * 1984-09-25 1985-09-10 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Decapeptide having gonadotropin releasing activity
US4721775A (en) * 1985-08-26 1988-01-26 Board Of Regents, The University Of Texas System Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids
NO302481B1 (no) * 1990-10-16 1998-03-09 Takeda Chemical Industries Ltd Polymer for et preparat med forlenget frigjöring, samt preparat med forlenget frigjöring
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
CA2192773C (en) * 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
AU3388597A (en) * 1996-06-13 1998-01-07 University Of Cape Town Human type ii gonadotropin-releasing hormone receptor

Also Published As

Publication number Publication date
MXPA01005543A (es) 2003-07-14
KR20010089538A (ko) 2001-10-06
AU770676B2 (en) 2004-02-26
RU2233170C2 (ru) 2004-07-27
HUP0104943A3 (en) 2002-08-28
IL143496A0 (en) 2002-04-21
NO20012636D0 (no) 2001-05-29
PL348575A1 (en) 2002-06-03
EP1140133A1 (en) 2001-10-10
NZ511984A (en) 2002-11-26
CZ20011893A3 (cs) 2002-05-15
BR9915943A (pt) 2001-08-21
ZA200104530B (en) 2002-06-04
JP2002531411A (ja) 2002-09-24
WO2000032218A1 (en) 2000-06-08
SK7552001A3 (en) 2002-02-05
CA2353798A1 (en) 2000-06-08
CN1332635A (zh) 2002-01-23
GB2344287A (en) 2000-06-07
EE200100293A (et) 2002-08-15
HUP0104943A2 (en) 2002-06-29
HRP20010421A2 (en) 2002-06-30
TR200102273T2 (tr) 2001-12-21
AU1573200A (en) 2000-06-19
GB9826662D0 (en) 1999-01-27

Similar Documents

Publication Publication Date Title
NO20012636D0 (no) Kontrollert frigivelsesformulering som omfatter GNRH-II
ATE269075T1 (de) Makrolid-formulierung mit verzögerter wirkstoffabgabe
DK1028961T5 (da) Pleuromutilinderivater som antimikrobielle midler
ID25533A (id) Formulasi 2-metil-tieno-benzodiazepin
ATE252386T1 (de) Galantamin-zusammensetzung mit gesteuerter freisetzung
IS5555A (is) Selekoxib lyfjablöndur
ID30031A (id) Formulasi-formulasi agrokimia
ID23546A (id) Formulasi-formulasi ziprasidon
BR9701304A (pt) Formulação de liberação prolongada
DK1109449T3 (da) Mikrokapselformuleringer
DK0973527T3 (da) Clarithromycinformuleringer med forlænget frigivelse
NO20004240D0 (no) Formuleringer
DK0922386T3 (da) Sammensætninger med reguleret frigivelse
NO20011738D0 (no) Heterocyclylaminometyloksazolidinoner som antibakterielle midler
ATE224703T1 (de) Brauseformulierungen
PT1130966E (pt) Formulacoes antiparasitarias
ATE254907T1 (de) Natriumhydrogendivalproat-formulierungen mit gesteuerter freigabe
NO20002126L (no) Formulering med forlenget frigjøring
DK0975623T3 (da) Indazolamidforbindelser som sertoninerge midler
DE60009106D1 (de) Mikrokapseln mit veränderlicher freisetzung
ATE232683T1 (de) Mikrokapsel-formulierungen
DE19983627T1 (de) Knoblauch-Formulierungen mit kontrollierter Freisetzung
NO20021452D0 (no) Orale kontrollerte frigivelsesformuleringer
DE69814051D1 (de) Trennmittel
FI971590A0 (fi) Anordning foer foerdelning av inluft till rumsutrymmen som skall luftkonditioneras

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application